NCT07600736RecruitingPhase 2
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-related Epilepsy
A Phase 1b/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 Administered to Pediatric and Young Adult Participants With KCNT1-Related Epilepsy
Source: ClinicalTrials.gov · Last updated 15 Oct 2026
Brief summary (registry, in English)
This trial will evaluate the safety, tolerability, pharmacokinetics, and clinical activity of ABS-1230 compared with placebo in participants with KCNT1-related epilepsy
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 61 (estimated)
- First submitted
- 14 May 2026
- Start date
- 18 May 2026
- Primary completion date
- 31 Jan 2027
- Lead sponsor
- Actio Biosciences, Inc.
- Diseases
- Epilepsy
- NCT number
- NCT07600736
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 61
- From 18 May 2026 to the primary completion date, 31 Jan 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Is currently taking phenytoin, carbamazepine, stiripentol, or quinidine
Other illness
- Has a medical condition that, in the opinion of the investigator, would limit the participant's ability to participate in the study or might compromise participant safety or interfere with evaluation of the study drug.
Who the study is looking for
- Aged 1 month to \<22 years
- Clinician-confirmed diagnosis of KCNT1-related epilepsy
- Has an average of at least 4 countable motor seizures per week
- Is taking no more than 6 antiseizure medications (ASM) and is able to keep stable doses of ASMs for the duration of Part 1 or Part 2
Age in the registry: 1 month to 21 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Northeast Regional Epilepsy Group Coordinator of this site? Confirm its status | Hackensack | United States | Recruiting |
| University of Rochester Medical Center Coordinator of this site? Confirm its status | Rochester | United States | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.